索拉非尼治疗复发难治性儿童神经母细胞瘤：4例经验
Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
作者信息
Okada Keiko, Nakano Yoshiko, Yamasaki Kai, Nitani Chika, Fujisaki Hiroyuki, Hara Junichi
机构信息
Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.
出版信息
Cancer Med. 2016 Aug;5(8):1947-9. doi: 10.1002/cam4.784. Epub 2016 Jun 5.
Abstract
Metastatic neuroblastoma is an aggressive malignancy with a poor prognosis. Recent findings have shown that sorafenib decreases cell viability and increases apoptosis in human neuroblastoma cell lines. We report an experience of compassionate use of sorafenib in children with treatment-refractory neuroblastoma. Sorafenib showed transient anti-tumor activity in all four patients without adverse effects. However, progression was observed after a short stabilization phase. While sorafenib showed minimal anti-tumor activity in our patients, it might still be effective in patients with neuroblastoma in an earlier stage.
摘要
转移性神经母细胞瘤是一种侵袭性恶性肿瘤，预后较差。最近的研究结果表明，索拉非尼可降低人神经母细胞瘤细胞系的细胞活力并增加细胞凋亡。我们报告了索拉非尼在治疗难治性神经母细胞瘤儿童中的同情用药经验。索拉非尼在所有四名患者中均显示出短暂的抗肿瘤活性，且无不良反应。然而，在短暂的稳定期后观察到疾病进展。虽然索拉非尼在我们的患者中显示出最小的抗肿瘤活性，但它可能对早期神经母细胞瘤患者仍然有效。
相似文献
1
Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
Cancer Med. 2016 Aug;5(8):1947-9. doi: 10.1002/cam4.784. Epub 2016 Jun 5.
2
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
Eur J Haematol. 2016 Jun;96(6):629-36. doi: 10.1111/ejh.12647. Epub 2015 Sep 21.
3
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.
4
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
Cancer Med. 2014 Oct;3(5):1275-83. doi: 10.1002/cam4.276. Epub 2014 Jun 10.
5
Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Endocrine. 2015 Aug;49(3):726-34. doi: 10.1007/s12020-014-0481-x. Epub 2014 Nov 21.
6
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
7
Refining sorafenib therapy: lessons from clinical practice.
Future Oncol. 2015;11(3):449-65. doi: 10.2217/fon.14.261. Epub 2014 Oct 31.
8
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Ann Oncol. 2012 Nov;23(11):2799-2805. doi: 10.1093/annonc/mds135. Epub 2012 Jul 5.
9
Sorafenib for the treatment of multiple myeloma.
Expert Opin Investig Drugs. 2016 Jun;25(6):743-9. doi: 10.1517/13543784.2016.1169272. Epub 2016 Apr 6.
10
Sorafenib in patients with refractory or recurrent multiple myeloma.
Hematol Oncol. 2013 Dec;31(4):197-200. doi: 10.1002/hon.2043. Epub 2013 Mar 15.
引用本文的文献
1
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Biochem Pharmacol. 2023 Oct;216:115751. doi: 10.1016/j.bcp.2023.115751. Epub 2023 Aug 16.
2
The cyclin dependent kinase inhibitor p21 is a therapeutic target in high-risk neuroblastoma.
Front Oncol. 2022 Sep 6;12:906194. doi: 10.3389/fonc.2022.906194. eCollection 2022.
3
PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.
Front Oncol. 2022 Jun 22;12:744984. doi: 10.3389/fonc.2022.744984. eCollection 2022.
4
Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults.
Front Oncol. 2022 May 25;12:864790. doi: 10.3389/fonc.2022.864790. eCollection 2022.
5
Transcriptomic Portraits and Molecular Pathway Activation Features of Adult Spinal Intramedullary Astrocytomas.
Front Oncol. 2022 Mar 21;12:837570. doi: 10.3389/fonc.2022.837570. eCollection 2022.
6
Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.
Molecules. 2021 Nov 23;26(23):7069. doi: 10.3390/molecules26237069.
7
A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.
J Exp Clin Cancer Res. 2021 Jun 8;40(1):189. doi: 10.1186/s13046-021-01967-x.
8
Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.
Br J Cancer. 2021 May;124(10):1637-1646. doi: 10.1038/s41416-021-01320-1. Epub 2021 Mar 15.
9
Use of Antiangiogenic Therapies in Pediatric Solid Tumors.
Cancers (Basel). 2021 Jan 12;13(2):253. doi: 10.3390/cancers13020253.
10
From old to new - Repurposing drugs to target mitochondrial energy metabolism in cancer.
Semin Cell Dev Biol. 2020 Feb;98:211-223. doi: 10.1016/j.semcdb.2019.05.025. Epub 2019 Jun 4.
本文引用的文献
1
The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
PLoS One. 2013 Nov 11;8(11):e78675. doi: 10.1371/journal.pone.0078675. eCollection 2013.
2
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update.
Hepatol Res. 2013 Feb;43(2):147-54. doi: 10.1111/j.1872-034X.2012.01113.x. Epub 2012 Nov 12.
3
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
Clin Cancer Res. 2013 Jan 1;19(1):236-46. doi: 10.1158/1078-0432.CCR-12-1897. Epub 2012 Nov 8.
4
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Clin Cancer Res. 2012 Nov 1;18(21):6011-22. doi: 10.1158/1078-0432.CCR-11-3284. Epub 2012 Sep 7.
5
Promising therapeutic targets in neuroblastoma.
Clin Cancer Res. 2012 May 15;18(10):2740-53. doi: 10.1158/1078-0432.CCR-11-1939.
6
Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
Cancer Biol Ther. 2012 May;13(7):534-41. doi: 10.4161/cbt.19603. Epub 2012 May 1.
7
Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.
Pediatr Blood Cancer. 2012 Oct;59(4):642-7. doi: 10.1002/pbc.24004. Epub 2011 Dec 6.
8
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
J Clin Oncol. 2011 Aug 20;29(24):3293-300. doi: 10.1200/JCO.2011.34.7427. Epub 2011 Jul 18.
9
Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line.
Int J Clin Exp Pathol. 2010 Apr 23;3(4):408-15.
10
Sorafenib and sunitinib.
Oncologist. 2009 Aug;14(8):800-5. doi: 10.1634/theoncologist.2009-0088. Epub 2009 Aug 1.
Zotero 插件